Timothy M. Swan

T 513.651.6775
F 513.651.6981
301 East Fourth Street
Great American Tower, Suite 3300
Cincinnati, Ohio 45202

Tim helps technology companies and companies dealing with technology issues. He takes a practical approach and invests the time to understand his clients' specific technologies and needs in order to help them achieve their goals efficiently.

For large and midsize clients, Tim helps prepare and negotiate licensing, collaboration, joint venture, development, professional services, contract research, manufacturing, clinical trial and other technology-related agreements. He has aided clients with large IT procurement projects.

For startups and emerging companies, Tim assists with similar complex technology matters, but also helps navigate formation, fundraising through equity and debt financing and corporate governance matters.

Tim has helped clients of all sizes on both buy and sell-side M&A transactions, with a focus on technology targets.

Industries of focus for Tim include the life sciences (including healthcare IT, pharmaceutical, medical device and biotechnology), agriculture technology, manufacturing, software, information technology, outsourcing, financial services and insurance.

Tim received his J.D. with high honors from the University of Chicago, where he was a member of the University of Chicago Law Review and the Order of the Coif. Before law school, Tim obtained his bachelor's degree in Mechanical Engineering and graduated magna cum laude from Rose-Hulman Institute of Technology, where he was captain of the Fightin' Engineers football team.

Prior to joining Frost Brown Todd, Tim was a partner in the Chicago office of Sidley Austin LLP.


  • GE Healthcare in connection with the formation of Intel GE Care Innovations, a joint venture with Intel Corporation to develop and market home-based health technologies; and its formation of Caradigm, a joint venture with Microsoft Corporation to develop and market a unified data aggregation and analysis platform for health care providers.
  • Lead strategic investor in $58 million Series B investment in an autonomous driving startup.
  • Advertising technology startup in $4.5 million Series A round and $1.5 million Series A-1 round.
  • Energy sciences startup in $600,000 seed round.
  • Healthcare IT startup in $4.5 million recapitalization.
  • Pharmaceutical CRO startup in $1 million Series A-1 round.
  • Institutional investor in $23 million Series A investment in material sciences company.
  • Institutional investor in acquisition of founders’ stock.
  • Healthcare IT company in its acquisition of a payments processing company.
  • GE Healthcare regarding IP aspects in a number of acquisitions, including Living Independently Group Inc., MicroCal LLC, Orbotech Medical Solutions Ltd., U-Systems, Inc., Steady State Imaging and part of Unisyn Medical Technologies.
  • Monsanto Company in its $300 million long-term strategic alliance with Novozymes to research and commercialize sustainable microbial products in the agriculture industry.
  • Catamaran in its acquisition by OptumRx (UnitedHealth Group's free-standing pharmacy care services business) for $12.8 billion, and in various licensing agreements.
  • Beam Inc. regarding IP aspects of its $16 billion acquisition by Suntory Holdings Limited.
  • Sara Lee Corp. in trademark licenses and other IP aspects of the nearly $1 billion sale of its North American fresh bakery business.
  • Morgan Stanley in a number of technology and business process outsourcing arrangements.
  • Global Healthcare Exchange in various license and services agreements, including its agreements with several group purchasing organizations.
  • Dicerna in its licensing of Tekmira's proprietary lipid nanoparticle technology for delivery of one of its RNAi candidates, with potential for $24.5 million in milestones in addition to ongoing royalties.
  • Takeda Pharmaceuticals Company regarding the IP aspects of its $800 million acquisition of URL Pharma, Inc.
  • The Hartford Financial Services Group on technology and transition matters in its divestiture of four businesses at the same time with a total price of over $1 billion, including retirement, individual life insurance, variable annuity and broker-dealer businesses.
  • GlaxoSmithKline plc regarding the IP aspects of its sale of a hepatitis C treatment candidate to Janssen Pharmaceuticals.
  • RoundTable Healthcare Partners regarding IP aspects in various pharmaceutical and medical device acquisitions, including its sale of CorePharma LLC and other companies to Impax Laboratories Inc. for $700 million and Aspen Surgical Products holding, Inc. to Hill-Rom Holdings, Inc. for $400 million.
  • Iridium Communications on a wide range of intellectual property and technology license and development agreements, including the intellectual property aspects of agreements underpinning the Iridium NEXT program.

Highlights & Recognitions

  • Rising Star for Technology, Media & Telecom / IT, LMG Expert Guides, 2015
  • Associate to Watch in Technology & Outsourcing, Chambers USA, 2013-2014
  • Recommended for Media, Technology and Telecoms, The Legal 500 US, 2013

Non-FBT Publications and Events

"The Risks in Electronic Trading Platforms Agreements" The Hedgefund Journal (August, 2015)  

"What Acquirers of Startups Look For: The IP Mistakes Startups Make" DILPA, September 14, 2018, Speaker

Other Contact Info


Coleen Mahoney
T 513.651.6493